DAC vs No DAC: Which CJC-1295 Fits Your Protocol
For most research protocols that need convenience and sustained IGF-1 elevation, CJC-1295 with DAC is the practical choice. For protocols prioritizing physiologic, pulsatile GH signaling, the no-DAC form — commonly called Modified GRF 1-29 (Mod GRF 1-29) — is preferable. The decision comes down to three variables: desired GH/IGF-1 exposure pattern, injection frequency tolerance, and how closely the protocol needs to mirror endogenous GH physiology.
Half-life and dosing frequency: CJC-1295 with DAC carries a terminal half-life lasting multiple days, supporting once- or twice-weekly injection schedules. Mod GRF 1-29 clears in a short time on the order of minutes, requiring daily or multiple-daily dosing to maintain GH stimulus.
GH/IGF-1 pattern: DAC produces a sustained, tonic elevation of baseline IGF-1 that persists for days after each injection. No-DAC generates a sharp GH pulse that mirrors the body’s own secretory pattern when timed correctly.
Regulatory and safety caveat: Neither form is FDA-approved for general clinical use in the United States. Both are classified as research compounds. Any human protocol requires IRB or equivalent oversight, and participants should be monitored for GH-class adverse effects.
Key Takeaways
CJC-1295 with DAC and Mod GRF 1-29 (no-DAC) share a GHRH receptor backbone but differ fundamentally in half-life, GH/IGF-1 exposure pattern, and the analytical rigor required to verify product identity — making the sourcing decision as important as the protocol decision.
Point Details Half-life contrast DAC carries a ~6–8 day terminal half-life; Mod GRF 1-29 clears in ~20–30 minutes, driving all dosing frequency differences. Signaling pattern DAC produces tonic IGF-1 elevation; no-DAC preserves pulsatile GH physiology when timed correctly to natural secretion windows. Safety monitoring Both require baseline metabolic panel, IGF-1, and fasting glucose; DAC’s extended exposure widens the adverse-effect window and demands longer washout. Sourcing standard DAC variants require mass spec confirmation of the intact modified molecule — HPLC purity alone cannot verify the albumin-binding modification is present and functional. PeptidesFromChina Supplies batch-traceable, COA-documented research-grade peptides with mass spec data available for DAC variants and independent third-party verification on request.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Table of Contents
What CJC-1295 is and how Mod GRF 1-29 relates to it
How the DAC modification changes the molecule’s pharmacology
Pharmacokinetics and dosing: half-life, injection schedules, and research regimens
Pulsatile versus sustained GH/IGF-1 exposure and downstream effects
When researchers or clinicians choose each variant
Safety signals, monitoring, and regulatory status in the US
Sourcing and quality control for US-based research procurement
How to choose between DAC and no-DAC for your protocol
Key studies, methodological notes, and reading the primary literature
An editorial perspective on DAC vs no-DAC in procurement and protocol design
Research-grade CJC-1295 with verified COA access through PeptidesFromChina
Sources
What CJC-1295 is and how Mod GRF 1-29 relates to it
CJC-1295 and Mod GRF 1-29 are both synthetic analogs of growth hormone-releasing hormone (GHRH), the endogenous 44-amino-acid peptide that signals the anterior pituitary to secrete GH. Both bind and activate the GHRH receptor (GHRHR), triggering the downstream GH/IGF-1 axis. Their shared pharmacological backbone means the receptor pharmacology is essentially the same — the difference is entirely in how long each molecule stays active in circulation.
The naming can confuse researchers new to this area. “CJC-1295 no DAC” and “Modified GRF 1-29” refer to the same compound: a 29-amino-acid truncated GHRH analog with four amino acid substitutions that improve stability relative to native GHRH. “CJC-1295 with DAC” is that same base sequence with an additional Drug Affinity Complex modification attached, which dramatically extends its plasma half-life. Some vendor catalogs label the no-DAC form simply as “CJC-1295,” which creates ambiguity — always confirm whether a product includes the DAC modification before ordering.
Key structural points:
Both share the same 29-residue GHRH-derived sequence with substitutions at positions 2, 8, 15, and 27 that resist DPP-IV cleavage.
The DAC modification is a chemical moiety added to the C-terminus that enables high-affinity, reversible binding to serum albumin.
Receptor binding affinity at GHRHR is comparable between the two forms; the pharmacokinetic profile diverges entirely because of albumin association.
Native GHRH itself has a plasma half-life of only a few minutes, making both analogs substantially more stable than the endogenous peptide.
How the DAC modification changes the molecule’s pharmacology
The Drug Affinity Complex is a maleimidoproprionic acid-based linker that forms a reversible, high-affinity bond with the free thiol group on serum albumin’s Cys-34 residue. Albumin circulates with a half-life of roughly 19 days in humans, and any peptide associated with it is effectively shielded from proteolytic degradation and renal filtration for as long as that association holds.
The practical consequence is a shift from a short-acting GHRH pulse to a prolonged receptor stimulus. With DAC attached, the peptide dissociates slowly from albumin, re-enters free circulation, binds GHRHR, and then re-associates with albumin — cycling through this equilibrium over days. The result is a sustained, tonic elevation of GH and IGF-1 rather than the discrete pulse that no-DAC produces.
From a manufacturing and QC standpoint, DAC variants present analytical challenges that no-DAC peptides do not:
Standard HPLC purity assessment is necessary but insufficient for DAC peptides. The albumin-binding moiety changes molecular weight and chromatographic behavior, so mass spectrometry confirmation of the intact modified molecule is required.
Albumin-binding assays or competitive displacement assays can verify that the DAC modification is functional, not just present on paper.
Stability under storage conditions differs: the maleimide linker can hydrolyze over time, particularly at elevated temperatures or in aqueous solution. Lyophilized storage at -20°C is standard; reconstituted DAC peptides should be used promptly or stored at 4°C for short periods only.
Batch-to-batch consistency in the DAC conjugation step is a real manufacturing variable. A supplier that cannot provide lot-specific mass spec data for DAC peptides is a sourcing risk.
Pharmacokinetics and dosing: half-life, injection schedules, and research regimens
The PK contrast between the two variants is the most empirically solid part of this comparison. A human dose-escalation trial documented a terminal half-life lasting multiple days for CJC-1295 with DAC, with single injections elevating IGF-1 for an extended period up to about two weeks at higher doses in the trial cohort. Pharmacokinetic characterizations of Mod GRF 1-29 place its plasma half-life in the range of roughly 20–30 minutes, a profile that supports short-acting, pulsatile dosing strategies.
Parameter Native GHRH Mod GRF 1-29 (No DAC) CJC-1295 with DAC Plasma half-life a few minutes ~20–30 minutes ~6–8 days IGF-1 elevation duration Minutes Hours (pulse-dependent) Days to ~2 weeks Typical injection frequency Continuous infusion (research) 1–3x daily, timed 1–2x weekly GH exposure pattern Pulsatile Pulsatile (preserved) Tonic/sustained baseline Primary research utility Endocrine physiology reference Pulse augmentation, mechanistic Sustained IGF-1 models, feasibility
Practical dosing regimens reported in community practice and vendor literature reflect these PK realities. DAC variants are commonly used at approximately 1–2 mg per week, split across one or two injections. Mod GRF 1-29 is typically dosed at approximately 100–200 mcg per injection, administered once to three times daily, often timed to coincide with natural GH release windows (pre-sleep or fasted morning).
Additional protocol considerations:
When co-administered with a GHRP (such as GHRP-2 or ipamorelin), Mod GRF 1-29 is injected simultaneously to amplify the GH pulse. DAC’s sustained background does not require this timing precision, though GHRP co-administration is still used in some stacks.
For GH sampling in studies, blood draws for peak GH should occur approximately 15–45 minutes post-injection with no-DAC. For IGF-1 monitoring with DAC, trough draws (just before the next weekly injection) provide the most stable and reproducible measure.
Reconstitution volume and injection concentration affect tolerability. Higher-concentration reconstitutions reduce injection volume but increase local peptide load at the injection site.
Pulsatile versus sustained GH/IGF-1 exposure and downstream effects
Endogenous GH secretion is pulsatile, driven by the interplay of hypothalamic GHRH and somatostatin. Pulses are most prominent during slow-wave sleep and in the fasted state. Endocrine physiology literature documents that this pulsatility is biologically meaningful: continuous GH receptor stimulation produces different downstream metabolic signaling consequences than episodic stimulation, including altered insulin sensitivity in some contexts.
Mod GRF 1-29, dosed once or twice daily, can approximate this pulsatile pattern. Each injection triggers a discrete GH peak lasting roughly 1–2 hours, after which GH returns toward baseline. The receptor experiences a high-amplitude, short-duration stimulus — closer to the physiologic norm.
CJC-1295 with DAC raises the GH/IGF-1 baseline continuously. Studies show this elevation is dose-dependent, with raised trough GH and sustained IGF-1 after DAC dosing, while pulse frequency may remain detectable in some settings. The receptor, however, is never fully unstimulated between pulses. Whether this matters clinically depends on the endpoint being studied.
The theoretical concerns with sustained exposure include:
Receptor desensitization or downregulation with prolonged tonic stimulation, though this has not been definitively demonstrated in human trials at research doses.
A wider window for GH-class adverse effects (water retention, peripheral edema, carpal tunnel-like paresthesia) because exposure is continuous rather than episodic.
Potential for greater IGF-1-driven insulin resistance signals over time, particularly relevant in metabolic studies or participants with pre-existing glucose dysregulation.
Statistic: In the Teichman et al. dose-escalation trial, single injections of CJC-1295 with DAC produced mean IGF-1 increases of 28–43% above baseline that persisted for 14 days at the higher dose levels in the small trial cohort — a duration no short-acting GHRH analog can replicate with a single injection.
When researchers or clinicians choose each variant
The choice between DAC and no-DAC maps directly to study design priorities. Neither variant is universally superior; each fits specific research aims.
Research aims suited to CJC-1295 with DAC:
Chronic exposure models where sustained IGF-1 elevation is the independent variable (body composition, tissue repair, metabolic adaptation studies).
Feasibility or compliance studies where daily injections are operationally impractical for participants.
Long-interval dosing pharmacodynamic studies examining trough IGF-1 stability and dose-response relationships.
Protocols where a stable, predictable IGF-1 baseline is needed across a multi-week intervention without frequent dosing adjustments.
Research aims suited to Mod GRF 1-29 (no-DAC):
Mechanistic endocrine studies where preserving pulsatile GH physiology is a design requirement.
Acute GH peak studies, pulse amplitude quantification, or GH secretagogue interaction research.
Protocols stacking a GHRH analog with a GHRP to study synergistic pulse augmentation.
Sleep-stage GH studies where timed nocturnal dosing is used to amplify the natural sleep-associated GH pulse.
When neither variant is appropriate:
Protocols requiring an FDA-approved therapeutic agent for a clinical indication. Neither form carries approval for therapeutic use in the United States.
Studies in populations with high baseline insulin resistance, active malignancy, or uncontrolled diabetes, where GH/IGF-1 elevation carries meaningful risk.
Any setting where IRB oversight or qualified medical monitoring cannot be provided.
Long-term safety studies: the evidence comparing clinical outcomes between sustained and pulsatile GH stimulation remains limited, and neither variant has a robust long-term human safety dataset.
Safety signals, monitoring, and regulatory status in the US
Both variants share the GH-class adverse effect profile. The primary signals are water retention, peripheral edema, carpal tunnel-like paresthesia, and transient insulin resistance. With DAC, the risk window is wider because exposure is continuous rather than episodic — a participant experiencing edema on a weekly DAC schedule cannot simply skip a dose and expect rapid clearance, given the 6–8 day half-life.
Monitoring checklist for research protocols:
Baseline: fasting glucose, HbA1c, fasting insulin, IGF-1, basic metabolic panel, and body weight.
During study: IGF-1 at each study visit (trough for DAC, post-peak for no-DAC); fasting glucose at minimum monthly; body weight and subjective edema assessment.
Adverse event triggers: new peripheral edema, paresthesia in hands or wrists, fasting glucose elevation above protocol threshold, or any unexpected endocrine symptom should prompt dosing pause and medical review.
Washout before follow-up labs: allow at least 3–4 weeks after last DAC injection before attributing lab values to a post-treatment baseline, given the extended half-life.
Regulatory status:
CJC-1295 in both forms is classified as a research compound in the United States. Neither is FDA-approved for general clinical use. Compounding pharmacies operating under 503A or 503B frameworks have faced regulatory scrutiny regarding peptide compounds, and the legal status of compounded GHRH analogs has shifted in recent years. Researchers should verify current FDA guidance before initiating any human protocol.
For sports-related research, the WADA prohibited list covers GH and related peptide secretagogues. Researchers working with competitive athletes must review WADA’s current list before study design to avoid inadvertent anti-doping violations.
Pro Tip: Before submitting an IRB protocol involving either CJC-1295 variant, confirm the compound’s current regulatory status with an FDA regulatory consultant or institutional compliance officer. The landscape for research peptides in the US has changed materially since 2020, and IRB boards vary in their familiarity with GHRH analogs.
Sourcing and quality control for US-based research procurement
The peptide supply chain for GHRH analogs involves several failure points that are specific to these molecules. DAC variants are more complex to synthesize and verify than standard linear peptides, and no-DAC forms are susceptible to DPP-IV degradation if stored improperly after reconstitution. Both require documentation that goes beyond a basic HPLC purity certificate.
Required QC artifacts for any CJC-1295 procurement:
Certificate of Analysis (COA) with HPLC purity (minimum 98% for research-grade material) and the specific chromatographic method used.
Mass spectrometry confirmation of molecular weight matching the expected sequence. For DAC variants, this must confirm the intact modified molecule, not just the base peptide.
Batch lot number with traceability to the synthesis run. A COA without a lot number cannot be independently verified.
Lyophilization records or confirmation that the product was lyophilized under controlled conditions. Incompletely lyophilized peptides retain residual moisture that accelerates degradation.
For injectable workflows: endotoxin testing (LAL or equivalent) and sterility data, or a clear statement that the product is not sterile and requires aseptic handling.
Common manufacturing pitfalls:
Incomplete DAC conjugation: the linker chemistry can fail partially, yielding a mixture of modified and unmodified peptide. A supplier without lot-specific mass spec data cannot rule this out.
Inaccurate mass spec interpretation: some vendors report nominal molecular weights without confirming isotope patterns or adduct ions, which can mask sequence errors.
Residual solvents from synthesis: acetonitrile and TFA are common in peptide HPLC purification and should be below ICH Q3C limits in research-grade material.
Mislabeling of DAC vs no-DAC: given that both forms share the same base sequence, a vendor without rigorous batch tracking can inadvertently supply the wrong variant.
Practical procurement workflow:
Request COA and mass spec data before placing an order. Any supplier that cannot provide these documents before purchase is not operating at research-grade standards.
Send a portion of each new batch to an independent third-party analytical lab (e.g., a US-based contract testing organization) for identity confirmation and purity verification. This is standard practice for any lab that publishes results based on these compounds.
Store lyophilized peptides at -20°C, away from light and moisture. Reconstituted solutions should be used within 30 days when stored at 4°C, and within 7 days for DAC variants given the maleimide linker’s aqueous stability limitations.
Document shipping conditions. Temperature excursions during transit can degrade peptide integrity before the product reaches the lab.
Pro Tip: For DAC variants specifically, request that the supplier provide albumin-binding verification data or a competitive displacement assay result alongside the standard COA. Standard HPLC purity alone cannot confirm that the DAC modification is functional — only that a molecule of approximately the right mass is present.
How to choose between DAC and no-DAC for your protocol
The following decision checklist maps the most common protocol constraints to a recommended variant. Work through each item in order; the first constraint that applies typically determines the choice.
Primary endpoint:
Acute GH peak, pulse amplitude, or pulsatile physiology study → Mod GRF 1-29 (no-DAC).
Sustained IGF-1 elevation, chronic exposure model, or body composition endpoint → CJC-1295 with DAC.
Mechanistic GHRP interaction or synergistic pulse study → Mod GRF 1-29 (no-DAC), timed with GHRP co-injection.
Operational constraints:
Participants cannot reliably self-inject daily → DAC (weekly dosing).
Protocol requires precise injection timing relative to sleep or meals → No-DAC (short half-life allows timing control).
Study duration is less than 4 weeks → Either variant is feasible; no-DAC offers faster washout.
Safety tolerance:
Participants with borderline fasting glucose or insulin resistance → No-DAC preferred; shorter exposure window limits metabolic risk.
Participants with history of edema or carpal tunnel → Either variant requires close monitoring; DAC carries higher sustained-exposure risk.
High-risk population (active malignancy, uncontrolled diabetes, pediatric) → Neither variant; redirect to approved agents or established protocols.
Stacking needs:
GHRP co-administration for pulse amplification → no DAC (timing-dependent synergy).
Standalone GHRH stimulus without GHRP → Either variant; no DAC offers simpler logistics.
Red flags that should redirect away from both variants:
Protocol requires an FDA-approved therapeutic agent for a clinical indication.
IRB approval or qualified medical monitoring cannot be secured.
Supplier cannot provide lot-specific COA with mass spec confirmation.
Study population has characteristics that make GH/IGF-1 elevation a meaningful safety risk.
Quick recommendation matrix: If the endpoint is mechanistic and pulsatility matters, use no-DAC. If the endpoint is chronic IGF-1 exposure and compliance is a constraint, use DAC. If neither condition is clearly met, start with no-DAC — its shorter half-life makes it easier to adjust, pause, or discontinue.
Key studies, methodological notes, and reading the primary literature
The evidence base for both variants is narrow. Most of what researchers cite comes from a small number of PK trials and endocrine physiology studies, not head-to-head clinical outcome RCTs.
Study / Source Design Key Endpoint Limitation Teichman et al. 2006 Dose-escalation PK trial, healthy adults, small n Terminal half-life ~6–8 days; IGF-1 elevation up to ~14 days (DAC) Small cohort; PK endpoints only, no clinical outcomes Mod GRF 1-29 PK characterizations PK modeling and short-duration human studies Half-life ~20–30 minutes; pulsatile GH response confirmed No long-term safety data; limited head-to-head comparison Pulsatile GH physiology literature Animal and human endocrine studies Pulsatility alters metabolic signaling vs continuous exposure Mechanistic; not directly translatable to analog dosing protocols DAC dose-response studies Small clinical cohorts, PK/PD endpoints Dose-dependent IGF-1 elevation; pulse frequency partially preserved PK endpoints; no body composition or long-term safety outcomes Frontiers in Endocrinology review Narrative/systematic review Limited clinical outcome evidence for sustained vs pulsatile GH stimulation Highlights evidence gap; does not resolve DAC vs no-DAC superiority
Methodological notes for researchers:
The Teichman 2006 trial is the most-cited primary source for DAC PK data, but its sample size is small and its endpoints are pharmacokinetic. Extrapolating from IGF-1 AUC to clinical outcomes requires caution.
No published RCT has compared body composition, muscle accretion, fat loss, or long-term safety between CJC-1295 with DAC and Mod GRF 1-29 in healthy adults. Recommendations in this area are reasoned from pharmacology, not clinical trial evidence.
Studies that report “preserved pulse frequency” with DAC dosing are measuring pulse frequency, not pulse amplitude or physiologic equivalence. A detectable pulse on top of a raised tonic baseline is not the same as a physiologic pulsatile pattern.
Designing a meaningful comparison study:
Pre-specify whether the primary endpoint is PK (IGF-1 AUC, peak GH), physiologic (pulse amplitude, frequency), or clinical (body composition, metabolic markers).
Include a washout period of at least 4–6 weeks between DAC and no-DAC arms in crossover designs, given the 6–8 day half-life and potential for residual IGF-1 elevation.
Control for injection timing, fasting state, sleep quality, and GHRP co-administration as confounders.
Power calculations should be based on IGF-1 variability data from the Teichman trial or similar PK studies, not assumed effect sizes.
An editorial perspective on DAC vs no-DAC in procurement and protocol design
The DAC vs no-DAC question gets oversimplified in most community discussions. The framing tends to collapse into “DAC for convenience, no-DAC for pulsatility” — which is accurate as far as it goes, but misses the procurement and analytical dimension that actually determines whether a study produces reliable data.
The more consequential variable, from a sourcing standpoint, is whether the supplier can verify what they sold. DAC peptides are harder to synthesize correctly and harder to verify analytically. A batch that is 95% pure by HPLC but contains 15% unconjugated base peptide (because the DAC conjugation step was incomplete) will behave like a mixture of DAC and no-DAC in vivo. That is not a theoretical risk — it is a real manufacturing failure mode that standard HPLC purity testing will not catch. Mass spec confirmation of the intact modified molecule is non-negotiable for DAC procurement.
For mechanistic work, starting with no-DAC is the more defensible choice. The shorter half-life means dosing errors are correctable, washout is fast, and the compound’s behavior in vivo is more predictable from the PK literature. DAC makes sense when the study design genuinely requires sustained IGF-1 elevation and the team has the monitoring infrastructure to manage a compound with a week-long half-life.
One practical note on switching between variants in a longitudinal study: if a protocol transitions from DAC to no-DAC (or vice versa), a washout of at least 3–4 weeks after the last DAC injection is a reasonable minimum before attributing any GH/IGF-1 measurements to the no-DAC phase. Community guidance suggests 2+ weeks based on half-life arithmetic, but given inter-individual variability in albumin turnover and DAC dissociation kinetics, the conservative approach is to extend that window.
Research-grade CJC-1295 with verified COA access through PeptidesFromChina
Researchers sourcing CJC-1295 variants for US-based protocols need more than a purity certificate. They need lot-specific mass spec data, confirmed lyophilization records, and a supplier with traceable batch documentation — particularly for DAC variants where standard HPLC alone cannot confirm the modification is functional.
PeptidesFromChina supplies research-grade peptides with batch-level COA documentation and direct relationships with synthesis facilities, not intermediary resellers. For DAC variants, mass spectrometry confirmation of the intact modified molecule is available alongside standard HPLC purity data. Independent third-party batch verification can be arranged on request for labs that require additional analytical confirmation before use.
These products are supplied for research use only and are not intended for human therapeutic use without appropriate regulatory approval and medical oversight. Procurement teams and research labs can review available inventory and COA documentation, or submit a sourcing inquiry, at Peptidesfromchina.